CN102906250A - 提高脂肪移植物存活率的方法和组合物 - Google Patents

提高脂肪移植物存活率的方法和组合物 Download PDF

Info

Publication number
CN102906250A
CN102906250A CN2011800205877A CN201180020587A CN102906250A CN 102906250 A CN102906250 A CN 102906250A CN 2011800205877 A CN2011800205877 A CN 2011800205877A CN 201180020587 A CN201180020587 A CN 201180020587A CN 102906250 A CN102906250 A CN 102906250A
Authority
CN
China
Prior art keywords
erythropoietin
epo
adipocyte
fat
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800205877A
Other languages
English (en)
Chinese (zh)
Inventor
沙赫尔·汗默德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remedor Biomed Ltd
Original Assignee
Remedor Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedor Biomed Ltd filed Critical Remedor Biomed Ltd
Publication of CN102906250A publication Critical patent/CN102906250A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
CN2011800205877A 2010-02-23 2011-02-23 提高脂肪移植物存活率的方法和组合物 Pending CN102906250A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30699110P 2010-02-23 2010-02-23
US61/306,991 2010-02-23
PCT/IL2011/000181 WO2011104707A1 (en) 2010-02-23 2011-02-23 Methods and compositions for enhancing fat graft survival

Publications (1)

Publication Number Publication Date
CN102906250A true CN102906250A (zh) 2013-01-30

Family

ID=44506187

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800205877A Pending CN102906250A (zh) 2010-02-23 2011-02-23 提高脂肪移植物存活率的方法和组合物

Country Status (12)

Country Link
US (1) US20120315254A1 (enExample)
EP (1) EP2539443B1 (enExample)
JP (2) JP5823986B2 (enExample)
CN (1) CN102906250A (enExample)
AU (1) AU2011219425A1 (enExample)
BR (1) BR112012021179A2 (enExample)
CA (1) CA2790867A1 (enExample)
IL (1) IL221619A (enExample)
IN (1) IN2012MN02218A (enExample)
MX (1) MX2012009768A (enExample)
RU (1) RU2012140379A (enExample)
WO (1) WO2011104707A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107456606A (zh) * 2017-08-30 2017-12-12 上海新肌生物科技有限公司 一种脂肪细胞存活率提高91%的复活素配方及制备方法
CN113413177A (zh) * 2021-06-23 2021-09-21 美闺(长沙)医疗美容有限公司 一种保持自体脂肪活性的移植设备及移植方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011219425A1 (en) * 2010-02-23 2012-10-18 Sebana Medical Ltd. Methods and compositions for enhancing fat graft survival
JP5953035B2 (ja) * 2011-11-28 2016-07-13 学校法人慶應義塾 病理診断支援装置、病理診断支援方法、及び病理診断支援プログラム
CN110229785A (zh) * 2019-06-17 2019-09-13 白晋 一种利用血管内皮祖细胞提升脂肪移植成功率的方法
CN111548988B (zh) * 2020-05-14 2023-06-20 江苏芝海生物科技有限公司 一种医用漂洗液及其制备方法和应用
CA3200227A1 (en) * 2020-11-25 2022-06-02 Alexandra Sophie DE BOER Adipogenic cell compositions and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
US20090018033A1 (en) * 2006-01-24 2009-01-15 Jeffrey Morgan Cell Aggregation and Encapsulation Device and Method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US7651684B2 (en) * 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
BRPI0411621A (pt) * 2003-06-18 2006-08-08 Macropore Biosurgery Inc métodos de uso de células derivados de tecido adiposo no aumento de transferência de gordura autóloga
PT1699915E (pt) * 2003-12-30 2010-08-31 Augustinus Bader Utilização de eritropoietina para a regeneração de tecido hepático
ITPD20050168A1 (it) * 2005-06-01 2006-12-02 Fidia Advanced Biopolymers Srl Formulazioni di acido lipoico ed acido ialuronico e o suoi derivati e loro impiego in campo farmaceutico e cosmetico
WO2008019434A1 (en) 2006-08-14 2008-02-21 Victorian Tissue Engineering Pty Ltd The use of growth factors in a method of improving fat-graft survival
EP2192907B1 (en) * 2007-08-16 2018-04-18 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic applications
AU2011219425A1 (en) * 2010-02-23 2012-10-18 Sebana Medical Ltd. Methods and compositions for enhancing fat graft survival

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
US20090018033A1 (en) * 2006-01-24 2009-01-15 Jeffrey Morgan Cell Aggregation and Encapsulation Device and Method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
周权 等: "促红细胞生成素在慢性心力衰竭的临床应用及机制研究进展", 《心血管病学进展》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107456606A (zh) * 2017-08-30 2017-12-12 上海新肌生物科技有限公司 一种脂肪细胞存活率提高91%的复活素配方及制备方法
CN113413177A (zh) * 2021-06-23 2021-09-21 美闺(长沙)医疗美容有限公司 一种保持自体脂肪活性的移植设备及移植方法
CN113413177B (zh) * 2021-06-23 2022-08-02 美闺(长沙)医疗美容有限公司 一种保持自体脂肪活性的移植设备及控制方法

Also Published As

Publication number Publication date
EP2539443A4 (en) 2013-12-11
RU2012140379A (ru) 2014-03-27
US20120315254A1 (en) 2012-12-13
EP2539443B1 (en) 2019-03-27
BR112012021179A2 (pt) 2015-09-15
IN2012MN02218A (enExample) 2015-06-12
JP6023864B2 (ja) 2016-11-09
IL221619A (en) 2017-09-28
AU2011219425A1 (en) 2012-10-18
EP2539443A1 (en) 2013-01-02
CA2790867A1 (en) 2011-09-01
MX2012009768A (es) 2013-02-27
JP2013520271A (ja) 2013-06-06
JP5823986B2 (ja) 2015-11-25
JP2016041261A (ja) 2016-03-31
WO2011104707A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
Zhang et al. Exosomes derived from platelet-rich plasma administration in site mediate cartilage protection in subtalar osteoarthritis
JP6023864B2 (ja) 脂肪移植物の生存を増大させるための方法及び組成物
TWI722400B (zh) 間質幹細胞之胞外泌體及其用途
Sun et al. Bone marrow mesenchymal stem cells and exercise restore motor function following spinal cord injury by activating PI3K/AKT/mTOR pathway
AU761592B2 (en) Introducing a biological material into a patient
EP2323626B1 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
Qin et al. Inhibition of SDF‐1/CXCR4 Axis to alleviate abnormal bone formation and angiogenesis could improve the subchondral bone microenvironment in osteoarthritis
Shen et al. 6-Bromoindirubin-3′-oxime promotes osteogenic differentiation of periodontal ligament stem cells and facilitates bone regeneration in a mouse periodontitis model
Rosochowicz et al. Conditioned medium–is it an undervalued lab waste with the potential for osteoarthritis management?
CN120346234B (zh) 一种增强优化型间充质干细胞外泌体在膝骨关节炎、肌软骨损伤中的应用
CN105377275A (zh) 用于静脉给药的干细胞组合物
EP3921029B1 (en) Composition comprising ccl5 for use in treating bone break, bone fracture, bone degeneration and osteoporosis
Li et al. Microenvironmental enzyme-responsive methotrexate modified quercetin micelles for the treatment of rheumatoid arthritis
JP2024512001A (ja) 腫瘍低酸素教育済み再生マクロファージを得る方法、及びその、再生医療における使用
Mazen et al. Therapeutic role of adipose tissue–derived stem cells versus microvesicles in a rat model of cerebellar injury
KR20250037691A (ko) 중간엽 줄기세포 스페로이드, 이의 제조방법 및 이를 포함하는 조성물
KR20160000030A (ko) 피부 또는 혈관조직 손상 치료 보조용 약학 조성물
El-Qashty et al. The role of erythropoietin-loaded hydrogel versus adipose derived stem cell secretome in the regeneration of tongue defects
Supanc et al. Traumatized muscle‐derived multipotent progenitor cells recruit endothelial cells through vascular endothelial growth factor‐A action
JPH08295634A (ja) 動脈疾患治療剤
Sava The development of a hydrogel-based regenerative therapy for brain tissue repair and functional recovery following ischaemic stroke
Sukpat et al. A low dose of simvastatin enhanced the therapeutic efficacy of mesenchymal stem cell (MSC) transplantation in skin wound healing in diabetic mice associated with increases in pAkt, SDF-1, and angiogenesis
AU2003242497B2 (en) Method and Pharmaceutical Composition Utilising Heparanase
Le Maitre Pathogenesis of disc degeneration: IL-1 as a therapeutic target
HK1222324B (zh) 用於静脉给药的干细胞组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130130